142576-91-8

Basic information

• Product Name: 3-CHLOROSULFONYL-2,6-DIFLUORO-BENZOIC ACID
• Synonyms: 3-CHLOROSULFONYL-2,6-DIFLUORO-BENZOIC ACID;Benzoic acid, 3-chlorosulfonyl-2,6-difluoro-
• CAS NO: 142576-91-8
• Molecular Formula: C₇H₃ClF₂O₄S
• Molecular Weight: 256.61
• Mol File: 142576-91-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-CHLOROSULFONYL-2,6-DIFLUORO-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLOROSULFONYL-2,6-DIFLUORO-BENZOIC ACID(142576-91-8)
• EPA Substance Registry System: 3-CHLOROSULFONYL-2,6-DIFLUORO-BENZOIC ACID(142576-91-8)

Safety Data

• Hazardous Substances Data: 142576-91-8(Hazardous Substances Data)

Upstream product

• 385-00-2 2,6-difluorobenzoic acid 

Downstream Products

• 845616-91-3 2,6-difluoro-3-sulfino-benzoic acid 
• 1572513-64-4 C₁₇H₁₄F₄N₂O₄S 
• 1572516-28-9 2,6-difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid 

Relevant articles and documents

SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS

The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and t

SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS

The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, R4, R5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.

BENZOYL-PIPERAZINE DERIVATIVES

The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

2-SACCHARINYLMETHYL ARYL CARBOXYLATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

A compound having the formula: STR1 wherein Ar, R 4 and R 5 are defined herein have pharmaceutical utility as proteolytic enzyme inhibitors.

PROTEOLYTIC ENZYME INHIBITION METHOD

4-R 4-R 5-2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R. sup.4-R 5-2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.